{"name": "Argos Therapeutics",
 "permalink": "argos-therapeutics",
 "crunchbase_url": "http://www.crunchbase.com/company/argos-therapeutics",
 "homepage_url": "http://www.argostherapeutics.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": 1997,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "",
 "phone_number": "(919) 287-6300",
 "description": "",
 "created_at": "Sat Jul 30 03:44:36 UTC 2011",
 "updated_at": "Sun Mar 31 11:45:26 UTC 2013",
 "overview": "\u003Cp\u003EArgos Therapeutics, Inc., a biotechnology company, engages in developing immunotherapy treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. The company has clinical trial programs in cancer and human immunodeficiency virus. Its products include AGS-0031 for metastatic renal cell carcinoma; AGS-0041 for HIV; CD83 soluble protein for transplant rejection/autoimmune disorders; Anti IFN-alpha monoclonal antibody2 for lupus; and regulatory T cell therapy3 for autoimmune disorders. The company was formerly known as MERIX Bioscience, Inc. Argos Therapeutics was founded in 1997 and is based in Durham, North Carolina.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       52],
      "assets/images/resized/0014/7029/147029v1-max-150x150.png"],
     [[167,
       58],
      "assets/images/resized/0014/7029/147029v1-max-250x250.png"],
     [[167,
       58],
      "assets/images/resized/0014/7029/147029v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "President \u0026 CEO",
    "person":
     {"first_name": "Jeffrey",
      "last_name": "D. Abbey",
      "permalink": "jeffrey-d-abbey",
      "image": null}},
   {"is_past": false,
    "title": "COO",
    "person":
     {"first_name": "Frederick",
      "last_name": "M. Miesowicz",
      "permalink": "frederick-m-miesowicz",
      "image": null}},
   {"is_past": false,
    "title": "board observer",
    "person":
     {"first_name": "Isaac",
      "last_name": "Cheng",
      "permalink": "isaac-cheng",
      "image": null}},
   {"is_past": true,
    "title": "Vice President and Chief Financial Officer",
    "person":
     {"first_name": "Timothy",
      "last_name": "W. Trost",
      "permalink": "timothy-w-trost",
      "image":
       {"available_sizes":
         [[[150,
            150],
           "assets/images/resized/0026/7048/267048v1-max-150x150.jpg"],
          [[200,
            200],
           "assets/images/resized/0026/7048/267048v1-max-250x250.jpg"],
          [[200,
            200],
           "assets/images/resized/0026/7048/267048v1-max-450x450.jpg"]],
        "attribution": ""}}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$25M",
 "funding_rounds":
  [{"round_code": "d",
    "source_url": "http://www.argostherapeutics.com/news/2012/news_20120424_argosfinancing-FastTrackDesignation_Final.html",
    "source_description": "Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012",
    "raised_amount": 25000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2012,
    "funded_month": 4,
    "funded_day": 24,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Forbion Capital Partners",
         "permalink": "forbion-capital-partners",
         "image":
          {"available_sizes":
            [[[150,
               60],
              "assets/images/resized/0010/0907/100907v1-max-150x150.png"],
             [[200,
               80],
              "assets/images/resized/0010/0907/100907v1-max-250x250.png"],
             [[200,
               80],
              "assets/images/resized/0010/0907/100907v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "TVM Capital",
         "permalink": "tvm-capital",
         "image":
          {"available_sizes":
            [[[150,
               35],
              "assets/images/resized/0003/0797/30797v1-max-150x150.png"],
             [[221,
               53],
              "assets/images/resized/0003/0797/30797v1-max-250x250.png"],
             [[221,
               53],
              "assets/images/resized/0003/0797/30797v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Lumira Capital",
         "permalink": "lumira-capital",
         "image":
          {"available_sizes":
            [[[150,
               53],
              "assets/images/resized/0013/3918/133918v1-max-150x150.jpg"],
             [[228,
               81],
              "assets/images/resized/0013/3918/133918v1-max-250x250.jpg"],
             [[228,
               81],
              "assets/images/resized/0013/3918/133918v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "InterSouth Partners",
         "permalink": "intersouth-partners",
         "image":
          {"available_sizes":
            [[[150,
               43],
              "assets/images/resized/0002/9315/29315v2-max-150x150.png"],
             [[250,
               71],
              "assets/images/resized/0002/9315/29315v2-max-250x250.png"],
             [[403,
               116],
              "assets/images/resized/0002/9315/29315v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "The Aurora Funds",
         "permalink": "the-aurora-funds",
         "image":
          {"available_sizes":
            [[[150,
               34],
              "assets/images/resized/0003/0298/30298v1-max-150x150.png"],
             [[250,
               58],
              "assets/images/resized/0003/0298/30298v1-max-250x250.png"],
             [[271,
               63],
              "assets/images/resized/0003/0298/30298v1-max-450x450.png"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "4233 Technology Drive",
    "address2": "",
    "zip_code": "27704",
    "city": "Durham",
    "state_code": "NC",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        117],
       "assets/images/resized/0017/4645/174645v1-max-150x150.png"],
      [[250,
        196],
       "assets/images/resized/0017/4645/174645v1-max-250x250.png"],
      [[450,
        353],
       "assets/images/resized/0017/4645/174645v1-max-450x450.png"]],
    "attribution": null}],
 "external_links":
  []}